Candida glabrata fungemia in the Intensive Care units

Hsueh, P.R., Ruan, S.Y., Lee, L.N., Jerng, J.S., Yu, C.J.

Author address: 

National Taiwan University Hospital, TAIPEI, Taiwan

Abstract: 

Background: Bloodstream infection due to Candida species is increasingly important in critical care. Among the non-albicans Candida, Candida glabrata has emerged as an important cause of fungemia in the intensive care units (ICUs). Methods: To describe the epidemiology, clinical features, antifungal susceptibilities of isolates, and treatment outcome of patients with C. glabrata fungemia hospitalized in adult ICUs in a university hospital in Taiwan from 2000 to 2005. Results: There were 147 episodes of candidemia occurring in ICUs, 45 (30%) of which were caused by C. glabrata. The incidence of Candida glabrata fungemia was 1.3 per 1000 ICU-admissions. Central venous catheter, gastrointestinal tract, and genitourinary tract were the three major portals of entry. Fluconazole resistance was found in 11% of C. glabrata isolates. Caspofungin and amphotericin B were highly active against C. glabrata. The 30 day all-cause mortality rate was 58%. Amphotericin B containing regimens were associated with better outcome. There was no significant difference in survival between patients with C. glabrata and non-glabrata candidemia. Conclusions: C. glabrata was the second most common species causing candidemia in adult ICUs. Despite higher fluconazole resistance, C. glabrata candidemia was not associated with higher mortality than non-glabrata candidemia.
2007

abstract No: 

P198

Full conference title: 

3rd Trends in Medical Mycology
    • TIMM 3rd (2011)